Literature DB >> 31516898

Contemporary approach to the patient with malignant pleural effusion complicating lung cancer.

Oleg Epelbaum1, Najib M Rahman2.   

Abstract

Malignant pleural effusion (MPE) occurring in the patient with lung cancer can have profound prognostic and management implications. If clinically relevant, such an effusion first needs to be confirmed as malignant and then, in the majority of lung cancer patients, it will require a pleural intervention to relieve symptoms related to fluid accumulation. The field of pleural diseases in general, and pleural malignancy in particular, has undergone dynamic changes in recent years as the evidence base informing practice has grown by leaps and bounds. Both the diagnosis and management of MPE are dynamically changing disciplines in thoracic medicine. As commonly happens, emerging data have generated just as many questions as they have answered. The aim of the present review is to summarize the current knowledge about MPE resulting from lung cancer in a manner that is accessible to clinicians across medical specialties.

Entities:  

Keywords:  Pleural effusion; indwelling pleural catheter (IPC); lung cancer; pleurodesis; thoracoscopy

Year:  2019        PMID: 31516898      PMCID: PMC6712251          DOI: 10.21037/atm.2019.03.61

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  62 in total

Review 1.  Management of malignant pleural effusions.

Authors:  V B Antony; R Loddenkemper; P Astoul; C Boutin; P Goldstraw; J Hott; F Rodriguez Panadero; S A Sahn
Journal:  Eur Respir J       Date:  2001-08       Impact factor: 16.671

2.  A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions.

Authors:  J B Putnam; R W Light; R M Rodriguez; R Ponn; J Olak; J S Pollak; R B Lee; D K Payne; G Graeber; K L Kovitz
Journal:  Cancer       Date:  1999-11-15       Impact factor: 6.860

3.  Malignant pleural effusions due to small-cell lung carcinoma: a cytologic and immunocytochemical study.

Authors:  D C Chhieng; E C Ko; H T Yee; J J Shultz; C C Dorvault; I A Eltoum
Journal:  Diagn Cytopathol       Date:  2001-12       Impact factor: 1.582

4.  Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion.

Authors:  Carolyn M Dresler; Jemi Olak; James E Herndon; William G Richards; Ernest Scalzetti; Stewart B Fleishman; Kemp H Kernstine; Todd Demmy; David M Jablons; Leslie Kohman; Thomas M Daniel; George B Haasler; David J Sugarbaker
Journal:  Chest       Date:  2005-03       Impact factor: 9.410

5.  Predictors of pleural malignancy in patients with pleural effusion undergoing thoracoscopy.

Authors:  Jaume Ferrer; Juan Roldán; Joan Teixidor; Esther Pallisa; Ignasi Gich; Ferran Morell
Journal:  Chest       Date:  2005-03       Impact factor: 9.410

6.  Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial.

Authors:  N A Maskell; F V Gleeson; R J O Davies
Journal:  Lancet       Date:  2003-04-19       Impact factor: 79.321

7.  Combination chemotherapy in patients with malignant pleural effusions from non-small cell lung cancer : cisplatin, ifosfamide, and irinotecan with recombinant human granulocyte colony-stimulating factor support.

Authors:  A Fujita; H Takabatake; S Tagaki; K Sekine
Journal:  Chest       Date:  2001-02       Impact factor: 9.410

8.  Pleurodesis practice for malignant pleural effusions in five English-speaking countries: survey of pulmonologists.

Authors:  Y C Gary Lee; Michael H Baumann; Nick A Maskell; Grant W Waterer; Tam E Eaton; Robert J O Davies; John E Heffner; Richard W Light
Journal:  Chest       Date:  2003-12       Impact factor: 9.410

9.  Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size.

Authors:  Nick A Maskell; Y C Gary Lee; Fergus V Gleeson; Emma L Hedley; Gerry Pengelly; Robert J O Davies
Journal:  Am J Respir Crit Care Med       Date:  2004-05-13       Impact factor: 21.405

Review 10.  Physiology and pathophysiology of pleural fluid turnover.

Authors:  L Zocchi
Journal:  Eur Respir J       Date:  2002-12       Impact factor: 16.671

View more
  6 in total

1.  Drug-eluting beads bronchial arterial chemoembolization plus intercostals arterial infusion chemotherapy is effective and well-tolerated in treating non-small cell lung cancer patients with refractory malignant pleural effusion.

Authors:  Xiaofei Liu; Hu Lin; Qin Wang; Mi Mu; Pan Pan; Fangfang Tian; Rui Zhang; Weiguo Zhao; Pengtao Bao
Journal:  J Thorac Dis       Date:  2021-04       Impact factor: 2.895

2.  Ubiquitin Conjugating Enzyme E2 H (UBE2H) Is Linked to Poor Outcomes and Metastasis in Lung Adenocarcinoma.

Authors:  Meng-Chi Yen; Kuan-Li Wu; Yu-Wei Liu; Yung-Yun Chang; Chao-Yuan Chang; Jen-Yu Hung; Ying-Ming Tsai; Ya-Ling Hsu
Journal:  Biology (Basel)       Date:  2021-04-28

3.  Developing a Prediction Score for the Diagnosis of Malignant Pleural Effusion: MPE Score.

Authors:  Chaichana Chantharakhit; Nantapa Sujaritvanichpong
Journal:  Asian Pac J Cancer Prev       Date:  2022-01-01

4.  Culture and multiomic analysis of lung cancer patient-derived pleural effusions revealed distinct druggable molecular types.

Authors:  Ha-Young Seo; Soon-Chan Kim; Woo-Lee Roh; Young-Kyoung Shin; Soyeon Kim; Dong-Wan Kim; Tae Min Kim; Ja-Lok Ku
Journal:  Sci Rep       Date:  2022-04-15       Impact factor: 4.996

5.  Palliative Care as an Adjunct to Standard Pulmonary Rehabilitation: A Pathway To Improving Functional Independence & Quality of Life in a Patient With Lung Cancer.

Authors:  Tasneem M Lakkadsha; Vaishnavi Yadav; Moli Jain; Shivani Lalwani; Sakina Saifee; Abdeali Saif A Kaderi
Journal:  Cureus       Date:  2022-08-30

6.  Laboratory and radiological discrimination between tuberculous and malignant pleural effusions with high adenosine deaminase levels.

Authors:  Jaehee Lee; Ji Eun Park; Sun Ha Choi; Hyewon Seo; Sang Yub Lee; Jae Kwang Lim; Seung Soo Yoo; Shin Yup Lee; Seung Ick Cha; Jae Yong Park; Chang Ho Kim
Journal:  Korean J Intern Med       Date:  2021-07-15       Impact factor: 2.884

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.